Advanced Cholangiocarcinoma: A New Era of Mechanisms and Management

To participate in this activity, please:

Survival outcomes for advanced cholangiocarcinoma remain suboptimal, despite first-line treatment with cytotoxic chemotherapy. Greater understanding of the pathobiology of cholangiocarcinoma has illuminated a variety of treatment targets, leading to several treatment advances. In this 0.5-hour activity, medical oncologist Lipika Goyal, MD, MPhil, discusses key concepts in navigating through the selection and use of these agents, including managing associated adverse events, helping shape the management of advanced cholangiocarcinoma to optimize patient care.

Course Credit:

0.5 AMA PRA Category 1 CreditsTM


Opens: 2023-10-25
Closes: 2024-10-25

Target Audience:

This activity is intended for oncologists, gastroenterologists, pathologists, and other healthcare providers caring for patients with cholangiocarcinoma.

This activity is supported by independent educational grants from Incyte and Taiho Oncology, Inc.


In support of improving patient care, Annenberg Center for Health Sciences at Eisenhower (Annenberg Center) is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

The Annenberg Center for Health Sciences at Eisenhower designates this enduring activity for a maximum of 0.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Additional Content Planners

Alexa Basilio, PharmD, BCOP (Medical Writer)
No significant relationships to disclose.

Jada Dillner, PA (Peer Reviewer)
No significant relationships to disclose.

Annenberg Center for Health Sciences

Staff at the Annenberg Center for Health Sciences at Eisenhower have no relevant financial relationships to disclose.

All of the financial relationships listed for these individuals have been mitigated.

    Presenting Faculty

  • Lipika Goyal, MD, MPhil

    Associate Professor of Medicine
    Stanford School of Medicine
    Director of Gastrointestinal Oncology
    Stanford Cancer Institute
    Palo Alto, California

Learning Objectives

  • Appreciate the unmet medical needs in advanced cholangiocarcinoma (CGA) with current therapies
  • Recognize the changing landscape with a focus on targetable mutations for the treatment of advanced CGA
  • Differentiate available targeted therapies and their associated efficacy, tolerability, and safety for the treatment of patients with advanced CGA
  • Discuss with patients how to navigate through the emerging landscape of targeted therapies for advanced CGA

Faculty Disclosures

Lipika Goyal, MD, MPhil

Advisory Board: AbbVie, Alentis Therapeutics AG, AstraZeneca, Blueprint Medicines, Eisai/H3 Biomedicine, Exelixis, Genentech, Incyte Corporation, Kinnate, Merck, Relay Therapeutic, Surface Oncology, The Servier Group, Taiho Oncology, TransThera Biosciences, Tyra Biosciences

Data Monitoring Safety Board: AstraZeneca

Other: Boehringer Ingelheim